Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Additional locations may be listed on ClinicalTrials.gov for NCT03340506.

Trial PhasePhase IV

Trial Typetreatment

Lead OrganizationNovartis Pharmaceuticals Corporation

• Primary IDCDRB436X2X02B
• Secondary IDsNCI-2017-02219, 000509-C
• ClinicalTrials.gov IDNCT03340506